MAP2K1 and esophageal squamous cell carcinoma: Hence, we confirmed that domperidone, acting as a “multi-target” agent, bind with the active site of the protein (MEK1/2 and CDK4), thereby interfered with its kinase activity to exert an antiproliferation role in ESCC.